UBXN11 and prostate cancer: A multicenter study involving 774 patients (255 training cohort, 519 validation cohort) across 22 sites within the United States demonstrated that the ExoDx assay combined with SOC variables was significantly better at predicting the presence of ≥ GGG 2 prostate cancer and negative biopsy results than either ExoDx assay or SOC variables alone (AUC combo: 0.77, gene alone: 0.74, SOC alone: 0.63) [23].